Literature DB >> 19344702

Effects of a new PAR1 antagonist, F 16618, on smooth muscle cell contraction.

Arnaud Bocquet1, Robert Létienne, Sylvie Sablayrolles, Luc De Vries, Michel Perez, Bruno Le Grand.   

Abstract

This study evaluated the effects of two PAR1 antagonists on vessels contracted by SFLLR. ER 121958 antagonized the SFLLR-induced contraction on rat denuded superior mesenteric artery and pig coronary artery in a non-competitive manner (IC(50) values were 22 [7.5-43.6] nM and 2.9 [2.09-4.02] nM, respectively). F 16618 inhibited the SFLLR-induced superior mesenteric arteries and coronary arteries contraction in a competitive manner (pA(2) values of 7.3 and 6.2, respectively). PAR1 antagonists do not affect vessel resting tension or haemodynamic parameters in anaesthetized rats. Thus, PAR1 antagonists could have beneficial effects against vasospasm due to vessel injury.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19344702     DOI: 10.1016/j.ejphar.2009.03.056

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  2 in total

1.  Antiplatelet and antithrombotic effect of F 16618, a new thrombin proteinase-activated receptor-1 (PAR1) antagonist.

Authors:  M Dumas; F Nadal-Wollbold; P Gaussem; M Perez; T Mirault; R Létienne; T Bourbon; F Grelac; B Le Grand; C Bachelot-Loza
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 2.  Antiplatelet therapy: thrombin receptor antagonists.

Authors:  Antonio Tello-Montoliu; Salvatore D Tomasello; Masafumi Ueno; Dominick J Angiolillo
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.